Randomized Study of Olaparib vs Placebo as Adjuvant Treatment in Patients with BRCA 1, 2 Mutations and High Risk HER2 Neg Primary Breast Cancer Who Have Completed Definitive Local Treatment and Adj or NeoAdj Chemotherapy (B55)

Randomized Study of Olaparib vs Placebo as Adjuvant Treatment in Patients with BRCA 1, 2 Mutations and High Risk HER2 Neg Primary Breast Cancer Who Have Completed Definitive Local Treatment and Adj or NeoAdj Chemotherapy (B55)

Trial Category:
Breast
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Faith Regional Health System, Carson Cancer Center, Norfolk, NE
Great Plains Health, Callahan Cancer Center, North Platte, NE
Nebraska Cancer Specialists, Omaha, NE
Nebraska Hematology Oncology, Lincoln, NE
Regional West Health Services, Cancer Center, Scottsbluff, NE
Southeast Nebraska Cancer Center, Lincoln, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members